E1	Condition:T1 Name:T2
E7	Procedure:T7 Name:T8 Temporality:E17
E9	Procedure:T9 Name:T10
E11	Procedure:T11 Name:T12
E13	Procedure:T13 Name:T14 Temporality:E19
E14	Age:T27 Eq-Comparison:E15
E15	Eq-Comparison:T35 Operator:T15 Temporal-Unit:T22 Value:T28
E16	Eq-Comparison:T36 Operator:T16 Value:T29
E17	Eq-Comparison:T37 Operator:T17 Temporal-Unit:T23 Value:T30
E18	Eq-Comparison:T38 Operator:T18 Temporal-Unit:T24 Value:T31
E19	Eq-Comparison:T39 Operator:T19 Temporal-Unit:T25 Value:T32
E20	Eq-Comparison:T40 Operator:T20 Value:T33 Unit:T82 Per:T83
E21	Eq-Comparison:T41 Operator:T21 Value:T34 Unit:T86 Per:T26
E2	Procedure:T5 Name:T6
E3	Negation:T42 Negates:E2
E4	Study:T43
E5	Temporal-Connection:T44 Arg:E2 Arg2:E4
E8	Observation:T46 Name:T47 Eq-Comparison:E16
E10	Drug:T48 Name:T49
E12	Drug:T50 Name:T51
E22	Drug:T52 Name:T53
E23	Drug:T54 Name:T55
E24	Or:T56 Arg:E22 Arg2:E23
E25	Procedure:T57 Name:T58 Temporality:E26
E26	Eq-Comparison:T60 Temporal-Recency:T59
E27	Temporal-Connection:T61 Arg2:E25 Arg:E17
E28	Drug:T62 Name:T63 Temporality:E18
E33	Or:T72 Arg:E31 Arg2:E32
E34	Or:T73 Arg:E28 Arg2:E11
E35	Procedure:T74 Name:T75
E36	Temporal-Connection:T76 Arg:E18 Arg2:E37
E37	Study:T77
E38	Temporal-Connection:T78 Arg:E19 Arg2:E39
E39	Study:T79
E40	Observation:T80 Name:T81 Eq-Comparison:E20
E41	Observation:T84 Name:T85 Eq-Comparison:E21
E42	Or:T87 Arg:T4 Arg2:T3
E43	Condition:T88 Name:T89 Stage:E44
E44	Eq-Comparison:T90 Operator:T93 Unit:T94 Value:T91 Value2:T92
E45	Assertion:T95 Asserted:E3
E46	And:T96 Arg:E43 Arg2:E45
E47	Assertion:T97 Asserted:E2
E6	Study:T45
E48	Study:T98
E49	And:T99 Arg:E6 Arg2:E48
E50	Temporal-Connection:T100 Arg:E8 Arg2:E6
E51	Study:T101
E52	Temporal-Connection:T102 Arg:E41 Arg2:E51
E53	Study:T103
E54	Temporal-Connection:T104 Arg:E40 Arg2:E53
E29	Modifier:T64 Modifies:T63
E30	Modifier:T65 Modifies:T63
E31	Modifier:T66
E32	Modifier:T67 Modifies:T63
T1	Condition 112 103	Myasthenia Gravis Foundation of America
T2	Condition-Name 112 103	Myasthenia Gravis Foundation of America
T3	Life-Stage-And-Gender 43 39	female
T4	Life-Stage-And-Gender 33 29	Male
T7	Procedure 481 451	immunomodulation
T8	Procedure-Name 481 451	immunomodulation
T9	Procedure 636 593	plasma exchange
T10	Procedure-Name 636 593	plasma exchange
T11	Procedure 618 577	plasmapheresis
T12	Procedure-Name 618 577	plasmapheresis
T13	Procedure 697 647	Thymectomy
T14	Procedure-Name 697 647	Thymectomy
T15	Eq-Operator 45 41	≥
T16	Eq-Operator 257 240	≥
T17	Eq-Operator 488 458	within
T18	Eq-Operator 650 605	within
T19	Eq-Operator 709 659	<
T20	Eq-Operator 767 712	<
T21	Eq-Operator 832 766	<
T22	Eq-Temporal-Unit 55 50	years
T23	Eq-Temporal-Unit 498 467	months
T24	Eq-Temporal-Unit 659 613	weeks
T25	Eq-Temporal-Unit 720 669	months
T26	Eq-Unit 851 780	mm3
T27	Age 62 57	age
T28	Eq-Value 49 44	18
T29	Eq-Value 261 242	12
T30	Eq-Value 491 460	6
T31	Eq-Value 653 607	4
T32	Eq-Value 713 662	12
T33	Eq-Value 770 713	6
T34	Eq-Value 838 770	1500
T35	Eq-Comparison 55 50	≥ 18 years
T36	Eq-Comparison 261 242	≥12
T37	Eq-Comparison 498 467	within 6 months
T38	Eq-Comparison 659 613	within 4 weeks
T39	Eq-Comparison 720 669	< 12 months
T40	Eq-Comparison 776 717	<6 g/L
T41	Eq-Comparison 851 780	<1500 cells/mm3
T5	Procedure 175 162	respirator
T6	Procedure-Name 175 162	respirator
T42	Negation 151 138	not
T43	Study 205 192	study
T44	Temporal-Connection 192 179	for the duration
T46	Observation 249 232	QMG
T47	Observation-Name 249 232	QMG
T48	Drug 408 380	rituximab
T49	Drug-Name 408 380	rituximab
T50	Drug 420 391	belimumab
T51	Drug-Name 420 391	belimumab
T52	Drug 433 403	eculizumab
T53	Drug-Name 433 403	eculizumab
T54	Drug 460 430	monoclonal antibody
T55	Drug-Name 460 430	monoclonal antibody
T56	Or 436 406	or
T57	Procedure 520 489	dosing
T58	Procedure-Name 520 489	dosing
T59	Eq-Temporal-Recency 513 482	first
T60	Eq-Comparison 513 482	first
T61	Temporal-Connection 504 473	prior
T62	Drug 546 511	Immunoglobulins
T63	Drug-Name 546 511	Immunoglobulins
T72	Or 578 538	or
T73	Or 603 562	or
T74	Procedure 641 597	PE
T75	Procedure-Name 641 597	PE
T76	Temporal-Connection 666 620	before
T77	Study 676 630	Screening
T78	Temporal-Connection 729 678	prior to
T79	Study 739 688	screening
T80	Observation 759 704	Total IgG
T81	Observation-Name 759 704	Total IgG
T82	Eq-Unit 772 715	g
T83	Eq-Unit 776 717	L
T84	Observation 830 764	Absolute neutrophil count
T85	Observation-Name 830 764	Absolute neutrophil count
T86	Eq-Unit 844 776	cells
T87	Or 36 32	or
T88	Condition 119 109	MGFA
T89	Condition-Name 119 109	MGFA
T90	Eq-Comparison 136 123	Class II-IVa
T91	Eq-Value 130 119	II
T92	Eq-Value 136 123	IVa
T93	Eq-Operator 132 120	-
T94	Eq-Unit 127 116	Class
T95	Assertion 147 134	likely
T96	And 140 127	and
T97	Assertion 162 149	need of
T45	Study 274 255	Screening
T98	Study 287 268	Baseline
T99	And 278 259	and
T100	Temporal-Connection 264 245	at
T101	Study 866 793	screening
T102	Temporal-Connection 856 783	at
T103	Study 791 731	screening
T104	Temporal-Connection 781 721	at
T64	Modifier 558 523	SC
T65	Modifier 563 527	IV
T66	Modifier 570 533	IVIG
T67	Modifier 598 558	intramuscular route
A1	Life-Stage-And-Gender-Type T3 female
A2	Life-Stage-And-Gender-Type T4 male
A3	Eq-Operator-Value T15 GTEQ
A4	Eq-Operator-Value T16 GTEQ
A5	Eq-Operator-Value T17 LTEQ
A6	Eq-Operator-Value T18 LTEQ
A7	Eq-Operator-Value T19 LT
A8	Eq-Operator-Value T20 LT
A9	Eq-Operator-Value T21 LT
A10	Eq-Temporal-Unit-Value T22 year
A11	Eq-Temporal-Unit-Value T23 month
A12	Eq-Temporal-Unit-Value T24 week
A13	Eq-Temporal-Unit-Value T25 month
A14	Temporal-Connection-Type-Value E5 during
A16	Observation-Type-Value T47 clinical-score
A17	Eq-Temporal-Recency-Value T59 first-time
A18	Temporal-Connection-Type-Value E27 before
A19	Temporal-Connection-Type-Value E36 before
A20	Temporal-Connection-Type-Value E38 before
A21	Observation-Type-Value T81 clinical-score
A22	Eq-Operator-Value T93 BETWEEN
A23	Assertion-Type-Value E45 hypothetical
A24	Assertion-Type-Value E47 hypothetical
A15	Temporal-Connection-Type-Value E50 during
A25	Temporal-Connection-Type-Value E52 during
A26	Temporal-Connection-Type-Value E54 during
R1	Using Arg1:E7 Arg2:E23
R2	Using Arg1:E7 Arg2:E22
R3	Using Arg1:E7 Arg2:E12
R4	Using Arg1:E7 Arg2:E10
R6	Abbrev-Of Arg1:E35 Arg2:E9
R7	Abbrev-Of Arg1:E43 Arg2:E1
R5	Abbrev-Of Arg1:E31 Arg2:E30
R8	Using Arg1:E28 Arg2:E11
R9	Using Arg1:E28 Arg2:E9